Patent – Validity. The Patents Court rejected all of Glaxosmithkline UK Ltd's challenges to the validity of a European patent for the prevention of serogroup B meningococcal disease. It ruled that GSK's 'Bexsero' (Men B) vaccine had infringed certain claims of the defendant's patent, save for claim 3.